Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 12, 2004 Bill Mann	ImClone's Mysterious Plunge Investors flee the stock the instant before it receives great news. Oops.
The Motley Fool March 8, 2004 Dave Marino-Nachison	Martha Looks Around the Corner Stewart watchers are now guessing at the future of the home-making empire.
The Motley Fool April 27, 2004 Alyce Lomax	Imagining ImClone It's been hard to ignore the lure of cancer drugs over the last several days. Today, ImClone shares leapt after the company reported stellar first-quarter profits, boosted by its launch of colon cancer drug Erbitux.
The Motley Fool May 21, 2004 Bob Bobala	Martha Surges on Perjury A bump in the Martha Stewart case sends her company's stock to the moon.
The Motley Fool March 18, 2004 Alyce Lomax	Is Kmart OK? Investors rejoice in the retailer's first profitable quarter since bankruptcy.
The Motley Fool January 12, 2004 Rex Moore	Martha Stewart's Web Spin With her trial just days away, Martha talks on MarthaTalks.com.
The Motley Fool May 19, 2004 Rick Aristotle Munarriz	Martha Gets Canned Martha Stewart Living Omnimedia takes a break from its plans for world domination.
The Motley Fool March 24, 2004 Rick Aristotle Munarriz	Martha Washing Done? The worst may be behind Martha Stewart's media empire. Is the stock a buy?
The Motley Fool September 16, 2004 Seth Jayson	Martha Cleans Up There's no disguising the fact that this is about repairing a brand in order to sell more magazines, more towels at Kmart, and more books on Amazon.com. But that should be worth something to shareholders.
The Motley Fool July 16, 2004 Brian Gorman	Martha's Light Sentence Martha Stewart Living Omnimedia investors cheered her light sentence, but the fate of the queen of the domicile probably isn't that important.
BusinessWeek March 8, 2004 Arnst & Ewing	The Odyssey Of A Cancer Drug How ImClone overcame scandal and FDA objections to get Erbitux to market
The Motley Fool May 3, 2004 Rich Smith	ImClone's Buy-and-Hold Lesson Long-term buy-and-hold investing could have saved Martha more than just jail time.
The Motley Fool January 30, 2004 David Murphy	Trying Times for Martha What does the Stewart trial mean for her company's bottom line?
The Motley Fool May 7, 2004 Alyce Lomax	A Martha Stewart Identity Crisis What's in a name? For Martha Stewart Living, it might be a matter of life-or-death.
The Motley Fool May 11, 2004 Seth Jayson	Martha: I'm Too Important for Jail Stewart's lawyers try to pull heartstrings in latest bid to keep Martha out of the slammer.
The Motley Fool March 10, 2005 Rick Aristotle Munarriz	Ratting Martha Out It really shouldn't come as much of a surprise to see Martha Stewart Living Omnimedia shares tumble in each of the four trading days since Martha's release. The stock has gone from $33.95 to $25.21 in that time. Maybe there's a way to get her back in jail?
The Motley Fool January 29, 2007 Brian Lawler	ImClone Fights The Competition The drug developer's performance has been alright, but the competition is heating up. Investors, take note.
The Motley Fool July 16, 2004 Tom Gardner	Martha Stewart, Was It Insider Trading? She was convicted of perjury, but did she make an illegal stock trade? Investment Intelligence from Insider Trading author weighs in.
ifeminists July 21, 2004 Carey Roberts	Martha Stewart Plays the Chivalry Card Studies have repeatedly found that when men and women commit the identical crime, women are less likely to be arrested, charged, convicted, and incarcerated.
The Motley Fool November 18, 2004 Rick Aristotle Munarriz	Marriage Means Stability for Martha The merger of Sears and Kmart is good news for Martha Stewart.
The Motley Fool July 20, 2006 Brian Lawler	No Surprises From ImClone ImClone's lead product experienced strong revenue growth in the second quarter. But biotech investing is fraught with risk. Investors, take note.
The Motley Fool April 27, 2004 Rich Duprey	Kmart, Martha Kiss and Make Up The retailer and homemaking diva patch up their partnership agreement.
The Motley Fool August 6, 2004 Rick Aristotle Munarriz	Martha Kids You Not Martha Stewart Living Omnimedia is taking a childish gamble with its newest magazine.
The Motley Fool August 3, 2004 Phil Wohl	Martha's Lockdown Mode The leading how-to company's walking a thin line with founder's legal trouble. For now, investors should continue to walk away from this mess.
Fast Company September 2004 Linda Tischler	The Trials of ImClone A founder in handcuffs, financials in disarray, and a vital product in doubt-for CEO Daniel Lynch, it was the turnaround from hell.
The Motley Fool March 1, 2007 David Lee Smith	Martha Stewart's Merchandise Bonanza Martha Stewart Omnimedia's Kmart partnership drives a strong quarterly performance. Investors inclined toward growing companies in the media sector should keep a close on the company's progress.
The Motley Fool March 7, 2005 Rick Aristotle Munarriz	Martha's Free, But Not Cheap Martha Stewart is free, but her stock is looking awfully expensive.
The Motley Fool October 28, 2005 Steven Mallas	Martha Can't Clean Up This Mess Martha Stewart Omnimedia reports a depressing loss. Investors may find other media plays more attractive right now.
The Motley Fool March 26, 2004 Bill Mann	Dynegy's First-Time Loser Jamie Olis is going to jail for a long time -- longer, in fact, than people who have done much worse.
BusinessWeek April 21, 2011 David Kamp	Book Review: Tangled Webs: How False Statements Are Undermining America by James Stewart Are we living through a sustained bull market for well-heeled liars?
The Motley Fool September 1, 2004 Bill Mann	Triumph of Hope Over Reason A frighteningly expensive drug of marginal efficacy begets triple-digit multiples? Bring on the miracles. Standard & Poor's reiterated its "buy" rating of ImClone.
The Motley Fool March 1, 2005 Seth Jayson	Another Head Rolls at Martha's Feet The publisher exits stage left. Martha Stewart Living Omnimedia's fourth quarter was abysmal, with the company getting worse in just about every way. So why is the stock flying?
The Motley Fool September 22, 2004 Rick Aristotle Munarriz	Send Your CEO to Jail! Martha Stewart's stock is going through the roof now that the walls are closing in on her.
BusinessWeek January 12, 2004	On Trial This year, the wheels of justice may catch up to some corporate movers and shakers.
The Motley Fool October 13, 2005 Selena Maranjian	Martha Stewart: Not a Good Thing for Me Did everyone who invested in Martha's stock suffer? Not at all. Short-term trading is risky, because no one knows what the market will do tomorrow, or even this year. Investing on margin is extra risky, and it's good to have a decent margin of safety if you do it.
The Motley Fool March 25, 2004 Selena Maranjian	The Least You Can Invest Don't think that you need to buy at least 100 shares.
The Motley Fool August 1, 2007 Brian Lawler	ImClone Inches Along ImClone reports slower than expected sales growth with its lead cancer fighting drug, Erbitux. ImClone needs to expand the use of Erbitux into new markets to return to a period of sustained top-line growth.
Reason October 2003 Michael McMenamin	St. Martha Why Martha Stewart should go to heaven and the SEC should go to hell.
The Motley Fool March 4, 2004 Dave Marino-Nachison	Martha Stewart's Stubborn Shares Uncertainty is hurting results, but the homemaking company's stock keeps rising.
BusinessWeek September 26, 2005 Robert Barker	A Flop For Martha's Investors From under $20 in May, MSO now is above $33.
U.S. CPSC January 19, 2005	Martha Stewart Living Omnimedia, Inc. Recall of Full Moon Lantern The lantern can overheat and melt or ignite, posing a burn hazard to consumers.
The Motley Fool October 18, 2004 Charly Travers	Biotech's 5-Baggers How can yesterday's biotech winners lead you to today's top performers?
The Motley Fool September 17, 2007 Lawrence A. Rothman	Martha Trades Blue Light for Red Star With K-Mart's sales down, Martha Stewart has decided to target middle-market shoppers by selling bedding, cookware, and dining pieces exclusively at Macy's. Alas, the department store has its own set of problems.
The Motley Fool March 4, 2004 Rick Aristotle Munarriz	Kicking the Kmart Curse Kmart isn't the kiss of death anymore. CEO Julian Day should bring good tidings to investors later this month, and a leaner, smarter Kmart sounds like a recipe for success.
U.S. Banker November 2001 Mark Bruno	Nasdaq Shows Sympathy On Sept. 27, Nasdaq declared an "across-the-board moratorium on the minimum bid and public float requirements," a move that will keep many battered stocks from being delisted...
Registered Rep. April 1, 2005	Fashion Sense for the Been-Set-Free Set The crocheted poncho Martha Stewart wore on her way out of prison has inspired the Web site sew-beautiful.us to begin selling knockoffs of the homemaking diva's coverup.
The Motley Fool April 28, 2008 Brian Lawler	ImClone on the Upswing The pharmaceutical's latest results show continuing improvement.
The Motley Fool November 14, 2005 Seth Jayson	Who Financed Martha's Flop? With Martha's Apprentice apparently over and done, it's time to reexamine who will pay the price for this dud. Let's simplify it: Martha and Mark Burnett created a failure. Shareholders paid them for it anyway.
The Motley Fool February 4, 2005 Seth Jayson	Bugs in Martha's Muffins Martha Stewart Living Omnimedia's stock continues to fly, but there's no rational reason for it.
The Motley Fool December 16, 2004 Paul Elliott	Do You Have the Guts to Buy? Growth investing is best served by a knack for spotting those rare birds that change the world -- and having the nerve to buy them when you do. But can it be done? You can't argue with success.